Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells.
Saved in:
| Title: | Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells. |
|---|---|
| Authors: | Fabilane CS; Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD, United States.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Tomala J; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States., Zdinak PM; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Center for Systems Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Graduate Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Chalmers BT; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Center for Systems Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Graduate Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Stephenson AC; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States., Ariail E; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Teeley EC; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States., Joglekar AV; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Center for Systems Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.; Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Spangler JB; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, United States.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Molecular Microbiology & Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Mar 09; Vol. 17, pp. 1755812. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1755812 |
